Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Gynecologic Cancer

• Publication date

  2003-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ijgc-00009577-200311001-00004PMID 14675308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Developmental chemotherapy and management of recurrent ovarian cancer.

  2003cited by this paper
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

  2002cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

  2000cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

  1996cited by this paper
• Advanced ovarian cancer. Carboplatin versus cisplatin.

  1993cited by this paper

• Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.

  2024cites this paper
• Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer

  2024cites this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2023cites this paper
• The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.

  2023cites this paper
• Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma

  2022cites this paper
• The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line

  2022cites this paper
• A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

  2022cites this paper
• High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

  2019cites this paper
• Bilateral synchronous ovarian tumours: an uncommon case and review of the literature

  2018cites this paper
• EXPLORATION OF METFORMIN EFFECT OVER OXALIPLATIN ANTINEOPLASIC PROPERTIES IN MKN45, KATOIII AND HS746T GASTRIC CANCER CELL LINES IN VITRO AND OVER OXALIPLATIN INDUCED RAT PAINFUL SENSORY NEUROPATHY IN VIVO.

  2018cites this paper
• Intraperitoneal Chemotherapy: Historic Anomaly or Hope for the Future?

  2018cites this paper
• Sab concentrations indicate chemotherapeutic susceptibility in ovarian cancer cell lines.

  2018cites this paper
• Nové trendy v systémové léčbě ovariálního karcinomu

  2018cites this paper
• The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer

  2017cites this paper
• Exploiting synthetic lethality in ovarian cancer

  2016cites this paper
• Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery

  2016cites this paper
• Evaluation of the impact of treatment delays and dose reductions in human ovarian cancer orthotopic mouse models

  2016cites this paper
• Chemotherapy of ovarian cancer in elderly patients

  2015cites this paper
• Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma

  2015cites this paper
• Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.

  2015cites this paper
• Ovarian cancer survival by tumor dominance, a surrogate for site of origin

  2015cites this paper
• Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway

  2015cites this paper
• Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management

  2014cites this paper
• Clinical features of taxane neuropathy

  2014cites this paper
• Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer

  2014cites this paper
• A Combination Therapy of JO-1 and Chemotherapy in Ovarian Cancer Models

  2014cites this paper
• A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

  2013cites this paper
• Clinical Course of Patients Treated for Advanced Ovarian Carcinoma without Surgical Intervention

  2013cites this paper
• Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review

  2013cites this paper
• Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

  2013cites this paper
• The Relationship Between Neuraxial Anesthesia and Advanced Ovarian Cancer-Related Outcomes in the Chilean Population

  2013cites this paper
• Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

  2013cites this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2013cites this paper
• Intraperitoneal, Continuous Carboplatin Delivery for the Treatment of Ovarian Cancer

  2012cites this paper
• INHIBITION OF SKOV3 OVARIAN CANCER BY NANOMICELLES CONSTRUCTED FROM POLY(ETHYLENE GLYCOL)- b -POLY(LACTIDE- co -CARBONATE/PACLITAXEL) CONJUGATES: INHIBITION OF SKOV3 OVARIAN CANCER BY NANOMICELLES CONSTRUCTED FROM POLY(ETHYLENE GLYCOL)- b -POLY(LACTIDE- co -CARBONATE/PACLITAXEL) CONJUGATES

  2012cites this paper
• Survivorship as an Element of Clinical Trials in Ovarian Cancer

  2011cites this paper
• Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

  2011cites this paper
• Potent cytotoxic effects of Calomeria amaranthoides on ovarian cancers

  2011cites this paper
• Patupilone in cancer treatment

  2011cites this paper
• Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient Outcomes

  2011cites this paper
• Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.

  2011cites this paper
• Systematic Lymphadenectomy for Survival in Epithelial Ovarian Cancer: A Meta-Analysis

  2010cites this paper
• Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

  2010cites this paper
• Considering Usual Medical Care in Clinical Trial Design

  2009cites this paper
• Rapid desensitization for hypersensitivity reactions to medications.

  2009cites this paper
• Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis.

  2009cites this paper
• Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.

  2009cites this paper
• Phase I/IIa Study of Combination Chemotherapy with CKD‐602 and Cisplatin in Patients with Recurrent Epithelial Ovarian Cancer

  2009cites this paper
• Intravenous Paclitaxel Is Specifically Retained in Human Gynecologic Carcinoma Tissues In Vivo

  2009cites this paper
• Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer.

  2009cites this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cites this paper
• Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

  2009cites this paper
• Ten years of “Optimal Therapy in Advanced Ovarian Cancer. Update” Meeting

  2008cites this paper
• Intraperitoneal chemotherapy in the treatment of late-stage ovarian cancer

  2008cites this paper
• Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

  2008cites this paper
• A terrible beauty: a physician's story of ovarian cancer.

  2007cites this paper
• Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

  2007cites this paper
• Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

  2007cites this paper
• Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

  2007cites this paper
• Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau

  2006cites this paper
• MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer

  2006cites this paper
• Rapid desensitization of hypersensitivity reactions to chemotherapy agents.

  2006cites this paper
• Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer.

  2006cites this paper
• A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer

  2006cites this paper
• Rapid desensitization for hypersensitivity reactions to chemotherapy agents

  2006cites this paper
• Phase I Study of Pegylated Liposomal Doxorubicin in Combination With Ifosfamide in Pretreated Ovarian Cancer Patients

  2006cites this paper
• One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.

  2006cites this paper
• Optimizing gemcitabine regimens in ovarian cancer.

  2006cites this paper
• Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.

  2006cites this paper
• Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last.

  2006cites this paper
• Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

  2006cites this paper
• What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate

  2005cites this paper
• Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain

  2005cites this paper
• Straight talk about ovarian cancer

  2005cites this paper
• The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells

  2005cites this paper
• Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer

  2005cites this paper
• Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.

  2005cites this paper
• Future options for first‐line therapy of advanced ovarian cancer

  2005cites this paper
• An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.

  2005cites this paper
• The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.

  2005cites this paper
• Topotecan: weighing in when there are many options.

  2005cites this paper
• The Gynecologic Cancer Intergroup (GCIG): history and current status.

  2005cites this paper
• Progression‐free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay

  2004cites this paper
• Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.

  2004cites this paper
• Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.

  2004cites this paper
• Surgery for ovarian cancer: rationale and guidelines.

  2004cites this paper
• Ovarian cancer treatment: what is new

  2003cites this paper